Fintel reports that on February 3, 2025, Redburn Atlantic upgraded their outlook for DexCom (NasdaqGS:DXCM) from Neutral to ...

The bull market of the past year or more has reinvigorated investors' interest across a range of industries, and the ...

Geneos Wealth Management Inc. lessened its position in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 2.6% in the ...

DexCom (NASDAQ:DXCM) shares received an optimistic update from Redburn-Atlantic, with analyst Issie Kirby (NYSE:KEX) upgrading the stock from Neutral to Buy and increasing the price target to $115 ...

Exchange Traded Concepts LLC decreased its position in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 12.4% in the ...

DexCom Inc. closed 38.30% below its 52-week high of $142.00, which the company achieved on March 26th.

DexCom stock shines with strong fourth quarter and full-year 2024 preliminary results, driven by innovation and global expansion. Explore if it's a buy or hold for your portfolio!

ClearPoint Neuro (CLPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings ...

sending the medical device maker's shares up nearly 6% premarket. Dexcom's shares had fallen nearly 37% last year, largely due to a slump in July after the company slashed its annual revenue ...

DexCom (NASDAQ:DXCM) shares popped 6% premarket on Monday after the company set its financial forecast for 2025, projecting adjusted gross profit margin of around 64% – 65% on revenue of $4.60B ...